177 335

Cited 0 times in

급성천식발작의 응급치료 성적 분석

Other Titles
 An analysis on the treatment outcome of acute asthma attack 
 김도영  ;  김대중  ;  신장열  ;  박효경  ;  김진석  ;  윤영연  ;  김철우  ;  박중원  ;  홍천수 
 Journal of Asthma, Allergy and Clinical Immunology (천식 및 알레르기), Vol.20(1) : 78-84, 1999 
Journal Title
Journal of Asthma, Allergy and Clinical Immunology(천식 및 알레르기)
Issue Date
Acute asthma attack ; β2 agonist ; Aminophylline ; A agonist
Background and objective .There has been little clinical data on the treatment outcome of pa- tients with acute asthma attack in Korea. We designed a management protocol of acute asthma, and analyzed clinical parameters obtained from this protocol. Method: A total of 32 cases with acute asthma were treated with oxygen, β2 agonist, and methylprednisolone. Ipratropium was added in cases of severe attack. After 90 minutes, intravenous aminophylline was given to the patients with poor response. Result: Beta2 agonist and methylprednisolone were sufficient for symptom control in 17 cases. Ipratropium and aminophylline were added in 6 and 9 cases, respectively. There was no difference in improvement of PEF, heart rate, respiratory rate, PaO2, PaCO2, and SaO2 at 90 minutes and 8 hours between agonist inhalation and subcutaneous group. Serum potassium concentration levels significantly decreased in patients treated with ipratropium or aminophylline (n15, 4.17+0.45 vs. 3.99±0.35mM/L, p<0.05), compared with patients using only agonist and methylprednisolone (n17, 3.89+0.30 vs. 4.14+0.46mM/L, p>0.05). Conclusion Subcutaneous agonist may be an alternative to inhalant 0z agonist for the emergency treatment of acute asthma, and we think that a consensus regarding use of aminophylline in the emergency room should be made.
Files in This Item:
T200002094.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Jung Won(박중원) ORCID logo https://orcid.org/0000-0003-0249-8749
Hong, Chein Soo(홍천수)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.